ANNAPOLIS, Md. and GAITHERSBURG, Md., April 26, 2017 (GLOBE NEWSWIRE) -- As previously announced, PharmAthene, Inc. (NYSE MKT:PIP) and Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious diseases, have signed a definitive agreement for the merger of PharmAthene and Altimmune in an all-stock transaction. Today, the companies announced that, pending approval of the merger between the two companies by PharmAthene’s stockholders at a special meeting of PharmAthene’s stockholders scheduled for May 4, 2017, the combined company has been approved for listing on the Nasdaq Global Market under the symbol “ALT.” If the merger is approved by PharmAthene’s stockholders and subsequently completed, trading of the combined company’s common stock on the Nasdaq Global Market is expected to commence on May 5, 2017, the day after the anticipated completion of the merger. PharmAthene’s common stock will continue to trade on the NYSE MKT until the completion of the merger, and, if the merger is not completed, PharmAthene’s common stock will continue to trade on the NYSE MKT.

John M. Gill, President and Chief Executive Officer of PharmAthene, and Bill Enright, President and Chief Executive Officer of Altimmune, commented: “We are pleased to announce the approval of the listing of the common stock of our combined company on the Nasdaq Global Market. We believe the move to Nasdaq is a natural step in connection with the merger between our two companies.”